The PTEN–PI3K Axis in Cancer

PTEN-opathies: from biological insights to evidence-based precision medicine

(2019) Lamis Yehia et al.   JOURNAL OF CLINICAL INVESTIGATION

An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer

(2018) Ming Chen et al.   NATURE GENETICS

The functions and regulation of the PTEN tumour suppressor: new modes and prospects

(2018) Yu-Ru Lee et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth

(2018) Helen B. Pearson et al.   Cancer Discovery

Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton

(2016) Hai Hu et al.   CELL

Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors

(2016) E. Toska et al.   CLINICAL CANCER RESEARCH

Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer

(2015) Carlotta Costa et al.   CANCER CELL

Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ

(2015) Sarit Schwartz et al.   CANCER CELL

Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity

(2015) Alexandra Van Keymeulen et al.   NATURE

PIK3CAH1047R induces multipotency and multi-lineage mammary tumours

(2015) Shany Koren et al.   NATURE

PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers

(2015) Q Wang et al.   ONCOGENE

The PTEN Tumor Suppressor Forms Homodimers in Solution

(2015) Frank Heinrich et al.   STRUCTURE

PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex

(2015) P. Liu et al.   Cancer Discovery

Regulation of the PI3K pathway through a p85α monomer–homodimer equilibrium

(2015) Lydia WT Cheung et al.   eLife

Suppression of T-cell lymphomagenesis in mice requires PTEN phosphatase activity

(2014) R. H. Newton et al.   BLOOD

Spatial Control of the TSC Complex Integrates Insulin and Nutrient Regulation of mTORC1 at the Lysosome

(2014) Suchithra Menon et al.   CELL

Cancer-Associated PTEN Mutants Act in a Dominant-Negative Manner to Suppress PTEN Protein Function

(2014) Antonella Papa et al.   CELL

Phosphoproteomics Screen Reveals Akt Isoform-Specific Signals Linking RNA Processing to Lung Cancer

(2014) Ioannis Sanidas et al.   MOLECULAR CELL

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

(2014) Dejan Juric et al.   NATURE

Discovery and saturation analysis of cancer genes across 21 tumour types

(2014) Michael S. Lawrence et al.   NATURE

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

PTEN-Deficient Tumors Depend on AKT2 for Maintenance and Survival

(2014) Y. R. Chin et al.   Cancer Discovery

Mouse models ofPIK3CAmutations: one mutation initiates heterogeneous mammary tumors

(2013) Shany Koren et al.   FEBS Journal

Development of PI3K inhibitors: lessons learned from early clinical trials

(2013) Jordi Rodon et al.   Nature Reviews Clinical Oncology

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1

(2013) H. Ebi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer

(2012) A.M. Gonzalez-Angulo et al.   CANCER TREATMENT REVIEWS

Systemic Elevation of PTEN Induces a Tumor-Suppressive Metabolic State

(2012) Isabel Garcia-Cao et al.   CELL

Physiological Levels of Pik3caH1047R Mutation in the Mouse Mammary Gland Results in Ductal Hyperplasia and Formation of ERα-Positive Tumors

(2012) Anjali Tikoo et al.   PLoS One

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer

(2012) Britta Weigelt et al.   Frontiers in Oncology

Insights into the oncogenic effects of /PIK3CA/ mutations from the structure of p110α/p85α

(2011) Chuan-Hsiang Huang et al.   CELL CYCLE

The Akt kinases: Isoform specificity in metabolism and cancer

(2011) Eva Gonzalez et al.   CELL CYCLE

The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations

(2011) H. Tanaka et al.   CLINICAL CANCER RESEARCH

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

(2011) Siyuan Zhang et al.   NATURE MEDICINE

Phosphoinositide 3-Kinase Pathway Activation in Phosphate and Tensin Homolog (PTEN)-deficient Prostate Cancer Cells Is Independent of Receptor Tyrosine Kinases and Mediated by the p110β and p110δ Catalytic Subunits

(2010) Xinnong Jiang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Subtle variations in Pten dose determine cancer susceptibility

(2010) Andrea Alimonti et al.   NATURE GENETICS

The emerging mechanisms of isoform-specific PI3K signalling

(2010) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Allele-specific tumor spectrum in Pten knockin mice

(2010) H. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase

(2010) R. B. Chagpar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer

(2009) Krishna M. Vasudevan et al.   CANCER CELL

p85 Associates with Unphosphorylated PTEN and the PTEN-Associated Complex

(2009) R. Rabinovsky et al.   MOLECULAR AND CELLULAR BIOLOGY

Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN

(2009) L Davidson et al.   ONCOGENE

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

(2009) Saskia M. Brachmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH

Class I PI3K in oncogenic cellular transformation

(2008) L Zhao et al.   ONCOGENE

PTEN-deficient cancers depend on PIK3CB

(2008) S. Wee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA